Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Salarius Pharmaceuticals, Inc. (SLRX)

2.42   -0.14 (-5.47%) 01-27 16:00
Open: 2.61 Pre. Close: 2.56
High: 2.76 Low: 2.35
Volume: 285,640 Market Cap: 6(M)

Technical analysis

as of: 2023-01-27 4:48:00 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.68     One year: 5.18
Support: Support1: 1.07    Support2: 0.89
Resistance: Resistance1: 3.15    Resistance2: 4.44
Pivot: 2.53
Moving Average: MA(5): 2.59     MA(20): 2.29
MA(100): 2.97     MA(250): 5.28
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 29.2     %D(3): 34.9
RSI: RSI(14): 52.7
52-week: High: 13.44  Low: 0.17
Average Vol(K): 3-Month: 168 (K)  10-Days: 745 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SLRX ] has closed above bottom band by 42.1%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.77 - 2.78 2.78 - 2.8
Low: 2.31 - 2.33 2.33 - 2.34
Close: 2.39 - 2.42 2.42 - 2.44

Company Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Headline News

Fri, 27 Jan 2023
Will Salarius Pharmaceuticals Inc (SLRX) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Fri, 20 Jan 2023
Healthcare Stocks Moving Friday: COSM, EAR, HOWL, INM, SLRX, RNXT, NRSN, EVLO - InvestorsObserver

Fri, 20 Jan 2023
Thinking about buying stock in Salarius Pharmaceuticals ... - PR Newswire

Fri, 20 Jan 2023
Premarket Mover: Salarius Pharmaceuticals Inc (SLRX) Up 10.89% - InvestorsObserver

Thu, 19 Jan 2023
U.S. stocks lower at close of trade; Dow Jones Industrial Average ... - Investing.com

Thu, 19 Jan 2023
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2 (M)
Shares Float 2 (M)
% Held by Insiders 6.1 (%)
% Held by Institutions 16.3 (%)
Shares Short 37 (K)
Shares Short P.Month 22 (K)

Stock Financials

EPS -0.38
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.38
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -40.4
Return on Equity (ttm) -99.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) -2.95
Sales Per Share 0
EBITDA (p.s.) -9.05
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -10 (M)

Stock Valuations

PE Ratio -6.42
PEG Ratio 0
Price to Book value 0.32
Price to Sales 0
Price to Cash Flow -0.36

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-07-21
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.